IPP Bureau
Shilpa Biologicals and mAbTree Biologics secure ODD from USFDA
By IPP Bureau - March 13, 2026
Marks significant milestone for breakthrough biologic to treat rare blood cancers
Punjab joins hands with Roche to roll out ‘NeuroSakhi’ for women with multiple sclerosis
By IPP Bureau - March 12, 2026
The NeuroSakhi initiative aims to close these gaps by strengthening awareness, building patient support networks and improving engagement between healthcare professionals, patients and caregivers across Punjab
Fortis launches 4 specialized clinics in Bengaluru to tackle under-discussed health issues
By IPP Bureau - March 12, 2026
The new facilities are designed to provide focused, patient-centric care through advanced diagnostics, minimally invasive treatments, and multidisciplinary expertise
World Glaucoma Week: Experts sound alarm over millions of undiagnosed cases in India
By IPP Bureau - March 12, 2026
Nearly 12 million people are estimated to be living with glaucoma, making the country one of the worst affected globally
BPL Medical Tech acquires South Korea’s Yozma BMtech
By IPP Bureau - March 12, 2026
Launches advanced bone density systems in India & Dubai
India tackles rare diseases head-on at landmark summit in New Delhi
By IPP Bureau - March 12, 2026
Industry leaders highlighted the pharmaceutical sector’s role in advancing research, innovation, early screening, and multi-stakeholder collaboration
Agilent to acquire Biocare Medical for $950M, supercharging cancer diagnostics portfolio
By IPP Bureau - March 12, 2026
The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
NewcelX and Eledon join forces to advance potential Type 1 diabetes cure
By IPP Bureau - March 12, 2026
The collaboration will leverage this clinical experience to inform NCEL-101 development, streamline regulatory pathways, and potentially accelerate timelines for achieving durable graft survival comparable to donor human islets
FDA nod to LifeVac De Novo, paving for next-generation anti-choking device
By IPP Bureau - March 12, 2026
The FDA classified LifeVac as a Class II medical device
Vertex Pharmaceuticals’ new kidney drug shows dramatic results in Phase 3 trial
By IPP Bureau - March 12, 2026
The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36
FDA nod to first treatment for rare genetic brain disorder
By IPP Bureau - March 12, 2026
The approval comes after a systematic review of published literature
EnteroBiotix completes enrollment in landmark microbiome trial for stem cell transplant patients
By IPP Bureau - March 12, 2026
The MAST trial is designed to test whether a single dose of pre-emptive, orally administered EBX-102-02 can protect and restore microbial diversity during transplantation
Kainova reports positive Phase I results for receptor antagonist targeting advanced tumors
By IPP Bureau - March 12, 2026
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
Zydus boosts companion diagnostics with AI-powered CGM Diasens and GlucoLive launch
By IPP Bureau - March 12, 2026
Diasens and GlucoLive are designed for diabetic, Chronic Kidney Disease (CKD), and post-transplant patients who require continuous glycaemic surveillance and integrated remote care
Alcon launches Hydrus Microstent in India to transform glaucoma care
By IPP Bureau - March 11, 2026
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
